All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.
Trial Details
- NCT ID
- NCT06158412
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- All-trans Retinoic Acid in combination with the KPD Regimen
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- Age ≥ 18 years.
- Subjects must have a diagnosis of multiple myeloma based on the following criteria: (1) Monoclonal plasma cells in the bone marrow in ≥10% of patie…
- Diagnosis of refractory/relapsed multiple myeloma: (1) Relapse is defined as the progression of disease after an initial response (≥MR) to prior th…
- ECOG assessment of 0, 1, or 2.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →